You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華-B(09969.HK)治療淋巴瘤藥物在海南博鼇樂城開出首個處方
阿思達克 07-22 09:09
諾誠健華-B(09969.HK)公布,tafasitamab (Minjuvi(R))聯合來那度胺已獲海南省衛健委和藥監局批准,在海南博鼇樂城國際醫療旅遊先行區用於治療不適合自體幹細胞移植(ASCT)條件的復發/難治彌漫性大B細胞淋巴瘤(DLBCL)成人患者。 得益於博鼇的政策,tafasitamab (Minjuvi(R))聯合來那度胺在博鼇樂城開出第一個處方,並在瑞金海南醫院為一名符合條件的DLBCL患者完成國內首例注射使用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account